Revolution Medicines, Inc.
RVMD
37 insider filings · Latest: Jun 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Jun 16, 2025 | Jun 13 9:25 PM | Wei Lin | Proposed Sale | 2,131 | $40.79 | $86.9K | — | View → |
| Jun 16, 2025 | Jun 13 9:05 PM | Kelsey Stephen Michael | Proposed Sale | 3,732 | $40.79 | $152.2K | — | View → |
| Jun 16, 2025 | Jun 13 9:03 PM | Horn Margaret A | Proposed Sale | 3,320 | $40.79 | $135.4K | — | View → |
| Jun 16, 2025 | Jun 13 9:00 PM | GOLDSMITH MARK A | Proposed Sale | 13,235 | $40.79 | $539.9K | — | View → |
| Jun 16, 2025 | Jun 13 8:58 PM | Cislini Jeff | Proposed Sale | 1,842 | $40.79 | $75.1K | — | View → |
| Jun 16, 2025 | Jun 13 8:55 PM | Anders Jack | Proposed Sale | 2,127 | $40.79 | $86.8K | — | View → |
| Mar 20, 2025 | Mar 20 8:32 PM | JEFFREY TODD CISLINI | Proposed Sale | 2,041 | $38.75 | $79.1K | — | View → |
| Mar 17, 2025 | Mar 14 9:42 PM | Anders Jack | Proposed Sale | 2,108 | $38.89 | $82.0K | — | View → |
| Mar 17, 2025 | Mar 14 9:14 PM | Cislini Jeff | Proposed Sale | 1,650 | $38.89 | $64.2K | — | View → |
| Mar 17, 2025 | Mar 14 8:47 PM | Kelsey Stephen Michael | Proposed Sale | 3,611 | $38.89 | $140.4K | — | View → |
| Mar 17, 2025 | Mar 14 8:18 PM | Horn Margaret A | Proposed Sale | 3,406 | $38.89 | $132.5K | — | View → |
| Mar 17, 2025 | Mar 14 8:09 PM | GOLDSMITH MARK A | Proposed Sale | 11,890 | $38.89 | $462.4K | — | View → |
| Jan 21, 2025 | Jan 21 9:20 PM | JEFFREY TODD CISLINI | Proposed Sale | 2,406 | $40.29 | $96.9K | — | View → |
| Dec 16, 2024 | Dec 17 2:35 AM | GOLDSMITH MARK A | Proposed Sale | 11,561 | $44.93 | $519.4K | — | View → |
| Dec 16, 2024 | Dec 17 1:42 AM | Kelsey Stephen Michael | Proposed Sale | 4,604 | $44.93 | $206.9K | — | View → |
| Dec 16, 2024 | Dec 17 1:01 AM | Cislini Jeff | Proposed Sale | 1,432 | $44.93 | $64.3K | — | View → |
| Dec 16, 2024 | Dec 17 12:39 AM | Horn Margaret A | Proposed Sale | 4,271 | $44.93 | $191.9K | — | View → |
| Dec 16, 2024 | Dec 16 9:57 PM | Anders Jack | Proposed Sale | 2,600 | $44.93 | $116.8K | — | View → |
| Nov 15, 2024 | Nov 15 9:44 PM | JEFFREY TODD CISLINI | Proposed Sale | 2,554 | $57.37 | $146.5K | — | View → |
| Nov 13, 2024 | Nov 13 9:30 PM | STEPHEN M. KELSEY | Proposed Sale | 16,666 | $59.33 | $988.8K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Jul 1 10:25 PM | Sushil PatelDirector | Option Exercise | 2,955 | $37.54 | 13,000(D) | View → |
| Jun 24, 2026 | Jun 26 8:10 PM | Jack AndersChief Financial Officer | Option Exercise | 20,000 | $18.56 | 20,600(D) | View → |
| Jun 18, 2026 | Jun 23 9:57 PM | Lorence H. KimDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:52 PM | Alexis BorisyDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:45 PM | Elizabeth M AndersonDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:45 PM | Sandra HorningDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:44 PM | Frank ClyburnDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:43 PM | Sushil PatelDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:42 PM | Flavia BorelliniDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 17, 2026 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Option Exercise | 29,600 | $40.74 | 114,275(D) | View → |
| Jun 15, 2026 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Option Exercise | 60,400 | $40.74 | 75,052(D) | View → |
| Jun 11, 2026 | Jun 15 8:05 PM | Margaret A HornChief Operating Officer | Option Exercise | 10,000 | $42.45 | 91,194(D) | View → |
| May 26, 2026 | May 28 8:10 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,121 | $33.62 | 106,109(D) | View → |
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,120 | $33.62 | 109,230(D) | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 120,000 | $4.73 | 424,085(D) | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 37,450 | $33.62 | 112,350(D) | View → |
| Mar 1, 2026 | Mar 4 2:11 AM | Xiaolin WangEVP, Clinical Development | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:10 AM | Lin WeiChief Medical Officer | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Stephen Michael KelseyPresident, Research and Development | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 30,000 | $4.09 | 47,708(D) | View → |
Page 1 of 2
Next →